Results 61 to 70 of about 53,085 (229)

The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype

Haematologica, 2008
Background Proteasome inhibition represents a promising novel anticancer therapy, and bortezomib is a highly selective reversible inhibitor of the proteasome complex.
Enrique Colado, Stela Álvarez-Fernández, Patricia Maiso, Jesús Martín-Sánchez, Maria Belén Vidriales, Mercedes Garayoa, Enrique M. Ocio, Juan Carlos Montero, Atanasio Pandiella, Jesús F. San Miguel   +9 more
doaj   +1 more source

N6-methyladenosine-modified circ_0000337 sustains bortezomib resistance in multiple myeloma by regulating DNA repair

Frontiers in Cell and Developmental Biology
Studies have shown that bortezomib resistance in multiple myeloma (MM) is mediated by the abnormalities of various molecules and microenvironments. Exploring these resistance mechanisms will improve the therapeutic efficacy of bortezomib.
Siyi Jiang, Lili Gao, Jian Li, Fangrong Zhang, Yanan Zhang, Jing Liu   +5 more
doaj   +1 more source

Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model

BMC Cancer, 2012
Background Despite recent advances in the treatment of hepatocellular carcinoma (HCC), the chemotherapy efficacy against HCC is still unsatisfactory.
Wang Cun, Gao Dongmei, Guo Kun, Kang Xiaonan, Jiang Kai, Sun Chun, Li Yan, Sun Lu, Shu Hong, Jin Guangzhi, Sun Haiyan, Wu Weizhong, Liu Yinkun   +12 more
doaj   +1 more source

Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib

Parasites & Vectors, 2009
The proteasome inhibitor and anti-cancer drug bortezomib was tested for in vitro activity against bloodstream forms of Trypanosoma brucei. The concentrations of bortezomib required to reduce the growth rate by 50% and to kill all trypanosomes were 3.3 nM
Wang Xia, Steverding Dietmar
doaj   +1 more source

Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United States.

PLoS ONE, 2016
This study is a pharmacoepidemiologic description of pediatric bortezomib use. Exposure was identified through billing codes in patients admitted to US children's hospitals that participated with the Pediatric Health Information System between 2004 and ...
Amanda M DiNofia, Elizabeth Salazar, Alix E Seif, Yimei Li, Yuan-Shung Vera Huang, Rochelle Bagatell, Brian T Fisher, Richard Aplenc   +7 more
doaj   +1 more source

Micro‐ and nanoplastics in gastrointestinal disorders: Mapping the translational gap between exposure, biomonitoring, and pathogenic mechanisms

BMEMat, EarlyView.
This review highlights critical “translational gaps” in understanding micro‐ and nanoplastics impacts on gastrointestinal diseases, bridging exposure, detecting, and mechanistic toxicology. Abstract Micro‐ and nanoplastics (MNPs) have become pervasive environmental contaminants with increasing evidence linking them to adverse health outcomes.
Zhenli Diao, Yujie Luo, Chuanda Zhu, Yanwei Hu   +3 more
wiley   +1 more source

Experimental study on forskolin combined with bortezomib inducing apoptosis in bortezomibresistant multiple myeloma cells

Zhongguo aizheng zazhi, 2016
Background and purpose: Although bortezomib has become one of the major therapeutic agents against newly diagnosed or relapsed multiple myeloma (MM), there are some patients who become resistant to bortezomib and then relapse, emerging as a major ...
王莹莹, 钟　瑶, 俞夜花
doaj  

The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells

Haematologica, 2015
Proteasome inhibitor resistance is a challenge for myeloma therapy. Bortezomib targets the β5 and β1 activity, but not the β2 activity of the proteasome.
Marianne Kraus, Juergen Bader, Paul P. Geurink, Emily S. Weyburne, Anne C. Mirabella, Tobias Silzle, Tamer B. Shabaneh, Wouter A. van der Linden, Gerjan de Bruin, Sarah R. Haile, Eva van Rooden, Christina Appenzeller, Nan Li, Alexei F. Kisselev, Herman Overkleeft, Christoph Driessen   +15 more
doaj   +1 more source

Circulating tumor plasma cells quantification in newly diagnosed transplant ineligible real world multiple myeloma patients: Comparison of single‐platform flow cytometry versus next generation flow

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Circulating tumor plasma cells (CTCs) at diagnosis are independent prognostic markers in newly diagnosed multiple myeloma (NDMM). Flow cytometry (FC) enables sensitive and cost‐effective CTC quantification, but prognostic cut‐offs vary across studies.
Elona Saraci, Alessandra Larocca, Roberto Ria, Silvia Mangiacavalli, Giulia Benevolo, Nicola Giuliani, Renato Zambello, Angelo Belotti, Ilaria Rizzello, Antonietta Pia Falcone, Iolanda Donatella Vincelli, Mariagrazia Michieli, Sonia Ronconi, Patrizia Tosi, Maria letizia Mosca Siez, Alessandro Allegra, Maide Maria Cavalli, Matilde Scaldaferri, Ilaria Fedele, Marco Burdisso, Tania Villanova, Cristina Velluti, Marcello Capriata, Donato Mannina, Anna Maria Cafro, Elisabetta Antonioli, Sonia Morè, Mario Boccadoro, Benedetto Bruno, Sara Bringhen, Mattia D'Agostino   +30 more
wiley   +1 more source

Bortezomib Prescription Pattern for the Treatment of Multiple Myeloma by Hematologists in Nigeria

Journal of Global Oncology, 2017
Purpose: Novel therapy has dramatically changed the outcome of patients with myeloma. Current National Comprehensive Cancer Network guidelines give bortezomib-based combinations a central role in the management of multiple myeloma (MM).
Kaladada I. Korubo, Anazoeze J. Madu, Helen C. Okoye, Benedict Nwogoh   +3 more
doaj   +1 more source